UPDATE : Monday, September 7, 2020
HLB to seek pre-NDA meeting with FDA for rivoceranib
HLB said it would request for a pre-New Drug Application (NDA) meeting with...
by Jeong Sae-im  |  2019-08-06 15:43
Roche, MSD, AstraZeneca: top 3 risers on NASDAQ biotech
Roche, MSD (Merck in the U.S.), and AstraZeneca achieved the most significa...
by Kim Yun-mi  |  2019-08-06 11:29
Pharmicell submits investigational new drug application for prostate cancer treatment
Pharmicell said that it has filed an investigational new drug application t...
by Lee Han-soo  |  2019-08-05 17:59
Sillajen’s trouble heralds fall of one of most prominent biotech firms
Shares of Sillajen continued to take a nosedive Monday after the biotech fi...
by Lee Han-soo  |  2019-08-05 16:55
SillaJen remains confident about Pexa-Vec’s value, despite trial failure
SillaJen said Pexa-Vec, an oncolytic viral drug, still had significant pote...
by Jeong Sae-im  |  2019-08-05 14:49
Suspicions resurge over SillaJen execs’ stock selling before Pexa-Vec trial suspension
With the likely suspension of SillaJen’s trial on its major anticancer pipe...
by Jeong Sae-im  |  2019-08-05 11:26
Biotech shares tank amid SillaJen’s likely halt of Pexa-Vec trial
Local biotech shares went down altogether on Friday after SillaJen said it ...
by Jeong Sae-im  |  2019-08-02 15:45
Eutilex pipelines are underrated: CEO
Eutilex CEO Kwon Byeong-se said he felt sorry for the recent fall of the co...
by Jeong Sae-im  |  2019-08-01 16:08
Samsung BioLogics records Q2 operating loss
Samsung BioLogics logged an operating loss of 5.4 billion won ($13.1 millio...
by Lee Han-soo  |  2019-07-25 10:16
Samsung Bioepis biosimilar sales in EU top $180 million in Q1
Samsung Bioepis’ sales in the European Union surpassed $180 million in the ...
by Lee Han-soo  |  2019-07-24 15:29
Celltrion Healthcare joins Australia's pharma industry group
Celltrion Healthcare said that it has joined Australia's Generic and Bi...
by Lee Han-soo  |  2019-07-22 15:13
Samsung BioLogics’ fate remains uncertain amid litigating ups and downs
The accounting fraud allegation involving Samsung BioLogics has been one of...
by Lee Han-soo  |  2019-07-19 18:16
EU starts evaluating Samsung Bioepis’ sales application for Avastin biosimilar
Samsung Bioepis said that the European Medicines Agency (EMA) has started e...
by Lee Han-soo  |  2019-07-19 17:01
Celltrion targets Chinese biosimilar market through joint venture
Celltrion said it has established Vcell Healthcare Ltd., a joint venture wi...
by Lee Han-soo  |  2019-07-19 14:53
Biopharmaceutical stocks face grim outlook in 2H
Biopharmaceutical stocks remain sluggish in the second half. Stock prices h...
by Jeong Sae-im  |  2019-07-17 14:11
Celltrion starts P1 trial of Xolair biosimilar
Celltrion said Monday that it initiated the phase 1 clinical trial of CT-P3...
by Lee Han-soo  |  2019-07-15 17:45
Doctors question Pexa-Vec+Imfinzi combo’s effect on colon cancer
Colon cancer specialists questioned SillaJen’s allegation that the combinat...
by Jeong Sae-im, Kim Yun-mi  |  2019-07-12 15:13
Court suspends decision on ministry’s order to revoke Invossa license
The Seoul Administrative Court on Thursday said it has temporarily suspende...
by Jeong Sae-im  |  2019-07-12 13:11
Prosecutors raid 2 lead managers of Kolon TissueGene’s IPO
The prosecution raided two securities firms that managed the initial public...
by Jeong Sae-im  |  2019-07-11 16:39
NKMax America seeks NASDAQ listing
“Seeking NASDAQ listing as soon as possible, we will show the excellent eff...
by Jeong Sae-im  |  2019-07-11 12:41
Back to Top